Home > News > Altair Nanotechnologies Announces New Preclinical Testing
February 5th, 2004
Altair Nanotechnologies Announces New Preclinical Testing
Altair Nanotechnologies, Inc., a developer and manufacturer of innovative nanomaterial products, announced that it is planning to conduct new preclinical testing of its drug candidate, RenaZorb. The test will use an animal model directly comparing RenaZorb with existing and proposed drugs for phosphate control in patients with End Stage Renal Disease undergoing dialysis. The testing is expected to be initiated within 30 to 45 days. The company also announced that it plans to file an IND application with the U.S. Food and Drug Administration.
Zenosense, Inc. July 29th, 2014
Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014
FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014
New imaging agent provides better picture of the gut July 25th, 2014